Phenyl and biphenyl substituted five-membered heterocyclic compounds and preparation methods, pharmaceutical compositions and applications thereof

By preparing 2-phenyl-5-biphenyl-substituted five-membered heterocyclic compounds, the problem of insufficient drug-likeness of existing PD-1/PD-L1 small molecule inhibitors has been solved, achieving highly efficient inhibition of PD-1/PD-L1 protein interaction and tumor treatment effects, and possessing good pharmacokinetic properties.

CN116041277BActive Publication Date: 2024-11-01CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310055621.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-18
Publication Date
2024-11-01
Estimated Expiration
2043-01-18

AI Technical Summary

Technical Problem

Existing PD-1/PD-L1 small molecule inhibitors have poor drug development, and there are problems such as drug resistance, immune-related adverse events and high treatment costs. Moreover, the development of small molecule inhibitors has not yet met the requirements for clinical application.

Method used

We will develop 2-phenyl-5-biphenyl-substituted five-membered heterocyclic compounds and prepare compounds with PD-1/PD-L1 protein-protein interaction inhibitory activity through Suzuki coupling, esterification, hydrazinolysis, condensation, cyclization and other reactions. We will then prepare these compounds into pharmaceutical compositions for the prevention and treatment of tumors, infectious diseases, inflammatory diseases and autoimmune diseases.

Benefits of technology

The compound exhibits high inhibitory activity against PD-1/PD-L1 protein interaction, can reverse immunosuppression, promote CD8+ T lymphocyte proliferation, increase the secretion of the cytokine interferon-γ, reduce the generation of regulatory T cells, significantly inhibit tumor growth, and shows favorable pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116041277B_ABST
    Figure CN116041277B_ABST
Patent Text Reader

Abstract

The present invention discloses a phenyl and biphenyl substituted five-membered heterocyclic compound and a preparation method, a pharmaceutical composition and an application thereof. The structure of the phenyl and biphenyl substituted five-membered heterocyclic compound is shown in Formula I, and also includes its stereoisomers, mesomers, racemates, prodrugs, crystals, pharmaceutically acceptable salts or mixtures thereof. The compound has PD-L1 inhibitory activity, can significantly inhibit PD-1 / PD-L1 protein-protein interaction, and block PD-1 / PD-L1 signaling pathway, and therefore can be used to prepare immunomodulator drugs for preventing and / or treating tumors, infectious diseases, inflammatory diseases, autoimmune diseases and organ transplant rejection. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a phenyl and biphenyl substituted five-membered heterocyclic compound, a preparation method, a pharmaceutical composition and an application thereof, and in particular to a phenyl and biphenyl substituted five-membered heterocyclic compound having inhibitory activity against PD-1 / PD-L1 protein-protein interaction, a preparation method, a pharmaceutical composition and an application thereof. Background Art

[0002] Immune escape is a basic biological characteristic of malignant tumors. Under normal physiological conditions, the human immune system can identify foreign molecules and eliminate them in a timely manner. However, for tumor patients, due to the low immune capacity of the body and the special biological characteristics of tumor cells, tumor cells can escape the recognition and killing of the immune system through various mechanisms, and eventually occur and develop in the body. Tumor immune escape is a complex pathological process, among which the escape mechanism mediated by immune checkpoints has attracted much attention.

[0003] Immune checkpoints are regulators of the human immune system. They are composed of a series of co-stimulatory molecules and co-inhibitory molecules, and play an important regulatory role in the body's immune system. The co-stimulatory molecules of immune checkpoints mainly include CD27, CD40, OX40, GITR, CD137, OX40 and ICOS, while the co-inhibitory molecules are mainly CTLA-4, PD-1, PD-L1, PD-L2, TIM-3, VISTA and IDO. Among them, co-stimulatory molecules can enhance the body's immune response, which is beneficial for immune cells to eliminate foreign molecules, while co-inhibitory molecules play a negative regulatory role in the immune response, thereby maintaining the body's immune homeostasis and avoiding excessive immunity and causing damage to the host's normal tissues. However, tumor cells can use immune checkpoints to achieve immune escape. Among them, the common escape mechanism is that tumor cells induce themselves, antigen presenting cells (APCs) and T lymphocytes to overexpress co-inhibitory molecules on their surfaces, thereby inhibiting the activation of T lymphocytes. Among them, programmed death receptor 1 (PD-1) and its ligands PD-L1 / 2 have received widespread attention as important co-inhibitory molecules in immune checkpoints. Currently, PD-1 / PD-L1 has been fully confirmed as a target for tumor immunotherapy.

[0004] In addition to being expressed on mature T cells, PD-1 can also be expressed at low levels on CD4 - CD8 -T cells, B cells, dendritic cells (DCs) and natural killer (NK) cells. PD-1 has two ligands, of which PD-L1 is mainly expressed in mature T cells, B cells and some non-hematopoietic cells, but PD-L1 can be expressed on a variety of cells under the induction of inflammatory factors (such as IFN-γ, TNF-α and VEGF). The expression range of PD-L2 is relatively narrow, mainly expressed in macrophages and DC cells. When PD-1 binds to its ligand, it causes tyrosine phosphorylation in the ITSM domain of the cytoplasmic region, thereby recruiting SHP-2 phosphatase near TCR, inhibiting the activation of TCR proximal kinase, resulting in a decrease in the phosphorylation level of ZAP-70 mediated by TCR-CD3 molecules and Lck, thereby activating its downstream signaling pathway. The negative regulation of PD-1 / PD-L on immunity is mainly through inhibiting the PI3K-AKT and RAS signaling pathways, blocking the activation of transcription factors that play an important role in T cell activation, proliferation, function and survival, such as activator protein-1 (AP-1), nuclear factor of activated T cells (NFAT) and NF-κB. In addition, T cell function can also be inhibited by upregulating the expression of transcription factor BATF.

[0005] Under normal physiological conditions, the PD-1 / PD-L signaling pathway can induce and maintain the tolerance of peripheral tissues during immune responses to prevent excessive immune responses in tissues. When the body is in a pathological state, excessive activation of the PD-1 / PD-L signaling pathway will inhibit the secretion of immunostimulatory factors such as IFN-γ, TNF-α and IL-2 and the expression of survival proteins. A large number of studies have shown that abnormalities in the PD-1 / PD-L signaling pathway are closely related to viral infections, diabetes, neurodegenerative diseases, organ transplant rejection and autoimmune diseases.

[0006] In addition, many studies have shown that abnormalities in the PD-1 / PD-L signaling pathway are closely related to the occurrence, development, and poor prognosis of a variety of human tumors. In the tumor microenvironment, when the PD-1 / PD-L signaling pathway is overactivated, tumor cells can survive by anti-apoptotic signals and inhibiting the activity of antigen-specific T lymphocytes. In addition, blocking the PD-1 / PD-L signaling pathway using PD-1 or PD-L1 antibodies can inhibit the growth of tumor cells. It mainly reverses the effects on T lymphocyte signal transduction, reactivates T lymphocytes, promotes the generation of effector T lymphocytes and memory T lymphocytes, and inhibits the differentiation of regulatory T lymphocytes, ultimately enhancing the immune killing ability of T lymphocytes in the tumor microenvironment, thereby achieving the purpose of treating tumors.

[0007] At present, more than 10 PD-1 / PD-L1 monoclonal antibody drugs such as Keytruda and Opdivo have been launched in the world, which are used in the clinical treatment of malignant melanoma, non-small cell lung cancer, gastric cancer, liver cancer, kidney cancer, bladder cancer and other solid tumors and blood cancers, greatly improving the prognosis of cancer patients and breaking the treatment bottleneck of many types of cancer. However, PD-1 / PD-L1 monoclonal antibody drugs have some obvious shortcomings. For example, due to its primary and / or acquired drug resistance, most cancer patients cannot benefit from it; due to its lack of oral bioavailability, it cannot be administered orally, and patient compliance is poor; coupled with its own immunogenicity, it is easy to cause drug-induced immune-related adverse events (irAEs) in patients; in addition, due to the difficulty of preparing and purifying monoclonal antibodies and the inconvenience of transportation, the treatment cost is high. These problems have limited the clinical application of PD-1 / PD-L1 monoclonal antibody drugs. It is worth mentioning that small molecule drugs, with their unique pharmacokinetic and pharmacodynamic properties, coupled with their low production costs, are expected to solve the defects of monoclonal antibody drugs, so the development of PD-1 / PD-L1 small molecule inhibitors has important application value. However, the development of such small molecule inhibitors is full of challenges, resulting in them still being in the early stages of development, far behind monoclonal antibody drugs. Therefore, there is an urgent need to develop new PD-L1 small molecule inhibitors with high activity and good drugability. Summary of the invention

[0008] Purpose of the invention: In view of the shortcomings of existing PD-1 / PD-L1 small molecule inhibitors, such as poor drugability, the present invention aims to provide a small molecule drug with significant PD-L1 inhibitory activity and its preparation method, pharmaceutical composition and application.

[0009] Technical solution: As the first aspect of the present invention, the 2-phenyl-5-biphenyl substituted five-membered heterocyclic compound of the present invention has a structure of formula I, which also includes its stereoisomers, mesomorphs, racemates, prodrugs, crystals, pharmaceutically acceptable salts or mixtures thereof,

[0010]

[0011] in:

[0012] The definitions of X, A, and B satisfy any of the following conditions:

[0013] (1) When X is O and A is N, B is C; when X is O and A is C, B is N or C;

[0014] (2) When X is S, A and B are N or C;

[0015] (3) When X is NH, A is N, and B is N;

[0016] (4) When X is N and A is N, B is O; when X is N and A is C, B is O or NH; when X is N and A is O, B is C or N;

[0017] R 1 is selected from methyl, cyano, hydroxyl or halogen;

[0018] R 2 is selected from hydrogen, halogen, nitro, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl or -O(CH2) n Ar; wherein n is an integer selected from 0-4; Ar is selected from an aryl group or an aromatic heterocyclic ring; the aromatic heterocyclic ring contains one or more heteroatoms selected from O, S or N; the C1-C4 alkyl, aryl or aromatic heterocyclic group is substituted by one or more W groups;

[0019] W is selected from hydrogen, halogen, cyano, hydroxyl, mercapto, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino or C1-C6 haloalkyl;

[0020] R 3 , R 4 Each is independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, C3-C8 cycloalkyl, 5-7 membered heterocyclyl or R 3 and R 4 Together with the nitrogen atom to which they are attached, they form a 5-7 membered heterocyclic group; the heterocyclic group may optionally contain one or more heteroatoms selected from O, S or N; the C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, C3-C8 cycloalkyl or 5-7 membered heterocyclic group is substituted by one or more Y groups;

[0021] Y is selected from hydrogen, halogen, hydroxyl, mercapto, methylthio, formyl, carboxyl, amino, guanidinyl, furanyl, tetrahydropyrrolyl, morpholinyl, N-methylpiperazinyl, C1-C4 alkyl, -CO2R 5 、-NHCOR 5 、-NR 6 R 7 or-CONR 6 R 7 ; The C1-C4 alkyl group is substituted by one or more hydroxyl groups or halogen groups;

[0022] R 5 Selected from C1-C8 alkyl;

[0023] R 6 , R 7 Each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or R 6 and R 7Together with the nitrogen atom to which they are attached, they form a 5-7 membered heterocyclic group; the C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or 5-7 membered heterocyclic group is substituted by one or more Z groups;

[0024] Z is selected from hydrogen, halogen, hydroxy, thiol, carboxyl, amino or acetamido.

[0025] The small molecule compound of the present invention has good inhibitory activity on PD-1 / PD-L1 protein-protein interaction and can be used to treat and / or prevent various related diseases caused by PD-1 / PD-L1-mediated immunosuppression.

[0026] Preferably, in the above structure:

[0027] R 1 is selected from methyl or halogen;

[0028] R 2 is selected from hydrogen, nitro or halogen;

[0029] R 3 , R 4 Each independently selected from hydrogen, C1-C5 alkyl or R 3 and R 4 Together with the nitrogen atom to which they are connected, they form a 5-6 membered N-containing heterocyclic group; the C1-C5 alkyl group or the 5-6 membered heterocyclic group is substituted by one or more Y groups;

[0030] Y is selected from hydrogen, hydroxy, formyl, carboxyl, guanidinyl, C1-C4 alkyl, -CO2R 5 、-NR 6 R 7 or-CONR 6 R 7 ; The C1-C4 alkyl group is substituted with one or more hydroxyl groups;

[0031] R 5 Selected from C1-C4 alkyl;

[0032] R 6 , R 7 Each is independently selected from hydrogen or C1-C4 alkyl.

[0033] Preferably, in the above structure:

[0034] R 1 is selected from methyl or chlorine;

[0035] R 2 is selected from hydrogen, nitro, fluorine, chlorine or bromine;

[0036] R 3 , R 4 Each independently selected from hydrogen, C1-C5 alkyl or R3 and R 4 Together with the nitrogen atom to which they are connected, they form a 5-6 membered heterocyclic group containing one N atom; the C1-C5 alkyl group or the 5-6 membered heterocyclic group is substituted by one or more Y groups;

[0037] Y is selected from hydrogen, hydroxy, formyl, carboxyl, guanidino, C1-C4 alkyl, -CO2CH3, amino or -CONH2; the C1-C4 alkyl is substituted by one or more hydroxyl groups.

[0038] Specifically, Select from the following ring systems:

[0039]

[0040] Selected from the following groups:

[0041]

[0042] More specifically, the above compound is selected from any one of the following compounds:

[0043]

[0044]

[0045]

[0046]

[0047]

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059] As the second aspect of the present invention, the preparation method of the above compound is as follows:

[0060] Method 1: When X is S, A and B are N, compound a-1 is used as a raw material to obtain a compound of formula (I) through Suzuki coupling, esterification, hydrazinolysis, condensation, cyclization, condensation reaction, or further through alkaline hydrolysis to obtain a compound of formula (I);

[0061]

[0062] Method 2: When X is NH, A and B are N, compound d-1 is subjected to cyclization, reduction, oxidation, and reductive amination to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0063]

[0064] Method 3: When X is N, A is O, and B is N, compound a-2 is subjected to addition, cyclization, reduction, oxidation, and reductive amination to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0065]

[0066] Method 4: When X and A are N, and B is O, compound a-3 is subjected to Suzuki coupling, addition, condensation, reduction, oxidation, reductive amination reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I);

[0067]

[0068] Method 5: When X is O, A is C, and B is N, compound a-4 is subjected to coupling, Suzuki coupling, bromination, and amination to obtain intermediate d-5, and intermediate d-5 is subjected to condensation, cyclization, reduction, halogenation, and condensation to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I); or intermediate d-5 is subjected to condensation and cyclization to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I);

[0069]

[0070] Method 6: When X is O, A is N, and B is C, compound b-1 is subjected to chlorination, condensation, cyclization, reduction, halogenation, condensation reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I);

[0071]

[0072] Method 7: When X is N, A is O, and B is C, compound b-1 is subjected to amination, cyclization, reduction, halogenation, and condensation to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0073]

[0074] Method 8: When X is N, A is C, and B is O, compound c-5 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0075]

[0076] Method 9: When X is N, A is C, and B is NH, compound c-5 is subjected to cyclization, reduction, halogenation, and condensation reaction to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0077]

[0078] Method 10: When X is S, A is C, and B is N, compound e-5-1 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0079]

[0080] Method 11: When X is S, A is N, and B is C, compound c-6 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I);

[0081]

[0082] Method 12: When X is S or O, and A and B are C, compound a-4 is subjected to coupling, coupling, bromination, Suzuki coupling, reductive amination reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I);

[0083]

[0084] Among them, R 1 , R 2 , R 3 , R 4 The definition of is as mentioned above.

[0085] As the third aspect of the present invention, the above-mentioned compounds can be prepared into PD-L1 inhibitor drugs and immunomodulator drugs, specifically drugs for preventing and / or treating tumors, infectious diseases, inflammatory diseases, organ transplant rejection and autoimmune diseases.

[0086] As the fourth aspect of the present invention, the above-mentioned compound and a pharmaceutically acceptable carrier form a pharmaceutical composition, and the specific preparation form is tablets, capsules, powders, pills, granules, injections, oral liquids, syrups, inhalants, ointments, patches or suppositories.

[0087] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:

[0088] The compounds of the present invention have high inhibitory activity on PD-1 / PD-L1 protein-protein interaction. Pharmacological experimental results show that these phenyl-substituted five-membered heterocyclic compounds have strong binding ability with PD-L1, can effectively reverse the immunosuppression mediated by PD-1 / PD-L1, and promote CD8 + The proliferation of T lymphocytes, increased secretion of cytokine interferon-γ, and decreased CD4 + CD25 + Foxp3 + The results of in vivo pharmacodynamic evaluation showed that the compounds of the present invention can significantly inhibit the growth of mouse transplanted tumors of various tumor types, but have no effect on the growth of transplanted tumors in nude mice with defective immune systems, indicating that these compounds have anti-tumor effects by activating the host immune response. BRIEF DESCRIPTION OF THE DRAWINGS

[0089] Figure 1 The figure shows the effect of the compound of the present invention on the activity of Lewis lung cancer cells at different concentrations.

[0090] Figure 2 The compounds of the present invention reversed the effect of PD-1 / PD-L1 in inhibiting the secretion of INF-γ by PBMC in a dose-dependent manner.

[0091] Figure 3 The compound of the present invention inhibits the growth of Lewis lung cancer transplanted tumor in mice in a dose-dependent manner.

[0092] Figure 4 The effect of the compounds of the present invention on T lymphocyte infiltration in mouse transplanted tumors, wherein: A) CD45 + cells; B) CD45 + CD3 + Cells; C) CD4 + CD45 + CD3 +cells; D)CD8 + CD45 + CD3 + cell. DETAILED DESCRIPTION

[0093] The technical solution of the present invention is further described below in conjunction with embodiments.

[0094] Reagents and materials: All reagents required for the experiments were of commercially available chemical or analytical grade unless otherwise specified.

[0095] instrument: 1 HNMR was measured by Bruker AV-300 and 400MHz nuclear magnetic resonance, chemical shift values ​​(δ) were in ppm, coupling constants (J) were in Hz, and TMS was used as the internal standard. The mass spectrometry (MS) analysis instrument was Shimadzu LCMS-2020 mass spectrometer; thin layer chromatography (TLC) used HG / T2354-92 GF254 thin layer chromatography silica gel produced by Qingdao Ocean Chemical Co., Ltd., and the color was developed by ZF7 three-purpose UV analyzer at 254nm; column chromatography used Qingdao Ocean Chemical Plant coarse pore (ZCX-II) type 300-400 mesh column chromatography silica gel.

[0096] Example 1: Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,3,4-thiadiazol-2-yl)benzyl)glycine (1) and its hydrochloride (1s)

[0097] Synthesis of 2-methyl-[1,1'-biphenyl]-3-carboxylic acid (1A)

[0098] 3-Bromo-2-methylbenzoic acid (10.00 g, 46.51 mmol), phenylboric acid (10.21 g, 83.72 mmol), potassium carbonate (7.71 g, 55.71 mmol) and Pd(PPh3)4 (0.53 g, 0.46 mmol) were added to 100 mL of 1,4-dioxane and 10 mL of water, and reacted at 80 °C for 12 h under nitrogen protection. The mixture was concentrated under reduced pressure, the pH was adjusted to 2 with 4 M HCl, filtered and dried to obtain 9.53 g of a white solid with a yield of 96%. MS (EI) m / z 211 [MH] - ; 1 HNMR(300MHz,Chloroform-d)δ(ppm)7.74-7.67(m,1H),7.50-7.38(m,3H),7.38-7.34(m,2H),7.33-7.28(m,2H),2.29(s,3H).

[0099] Synthesis of 2-methyl-[1,1'-biphenyl]-3-carboxylic acid methyl ester (1B)

[0100] 1A (9.53 g, 44.90 mmol) was added to 100 mL of methanol, and 5 mL of concentrated sulfuric acid was added dropwise under stirring. The mixture was refluxed for 4 h. After cooling, the mixture was concentrated under reduced pressure, and 300 mL of water was added. The mixture was extracted with ethyl acetate and washed with saturated brine. The organic phases were combined to obtain 9.96 g of a yellow oily liquid with a yield of 98%. MS (EI) m / z 225 [MH] - ; 1 HNMR (300MHz, Chloroform-d) δ (ppm) 7.45-7.32 (m, 4H), 7.30-7.15 (m, 3H), 7.07 (d, J = 7.5Hz, 1H), 3.98 (s, 3H), 2.32 (s, 3H).

[0101] Synthesis of 2-Methyl-[1,1'-biphenyl]-3-carbohydrazide (1C)

[0102] 1B (9.96 g, 44.02 mmol) was added to 100 mL of ethanol, and 5 mL of hydrazine hydrate was added, and the mixture was refluxed for 5 h. The mixture was cooled, concentrated under reduced pressure, and 100 mL of ice water was added to precipitate solids, which were filtered and dried to obtain 9.24 g of white solids with a yield of 93%. MS (EI) m / z 225 [MH] - ; 1 HNMR(300MHz,Chloroform-d)δ8.02(s,1H),7.45(d,J=7.5Hz,3H),7.37(s,1H),7.33(d,J=1.8Hz,3H),2.52(s,3H).

[0103] Synthesis of N'-(3-(Chloromethyl)benzoyl)-2-methyl-[1,1'-biphenyl]-3-carboxylic acid hydrazide (1D)

[0104] 3-(Chloromethyl)benzoic acid (0.25 g, 1.46 mmol) was added to 5 mL of anhydrous dichloromethane, 1 mL of oxalyl chloride was added dropwise, the reaction was continued for 3 h, the mixture was concentrated under reduced pressure, the mixture was dissolved in 3 mL of anhydrous dichloromethane, the mixture was added dropwise to a dichloromethane solution of 1C (0.32 g, 1.33 mmol) and triethylamine (0.21 g, 1.99 mmol) cooled in an ice bath, the reaction was continued for 3 h, the mixture was filtered and dried to obtain 0.45 g of a white solid, with a yield of 90%. MS (EI) m / z 377 [MH] - ; 1HNMR(300MHz,Chloroform-d)δ10.02(s,1H),8.74(s,1H),8.02(s,4H),7.37(td,J=15.0,13.5,9.0Hz,8H),4.70(s,2H),2.31(s,3H).

[0105] Synthesis of 2-(3-(chloromethyl)phenyl)-5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,3,4-thiadiazole (1E)

[0106] 1D (0.45 g, 1.19 mmol) and Lawesson's reagent (0.58 g, 1.43 mmol) were added to 10 mL of toluene and refluxed for 5 h. The mixture was concentrated under reduced pressure, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography [petroleum ether:ethyl acetate = 15:1 (V:V)] to obtain 0.32 g of a white solid with a yield of 71%. MS (EI) m / z 375 [MH] - ; 1 HNMR(300MHz,Chloroform-d)δ8.11(s,1H),8.01(dt,J=6.9,1.8Hz,1H),7.68(dd,J=6.6,2.4Hz,1H),7.56(s,1H),7.48(s,1 H),7.46(s,1H),7.43(s,1H),7.41(d,J=2.7Hz,2H),7.39(d,J=1.8Hz,2H),7.36(t,J=1.5Hz,1H),4.70(s,2H),2.46(s,3H).

[0107] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,3,4-thiadiazol-2-yl)benzyl)glycine methyl ester (1m)

[0108] 1E (0.32 g, 0.85 mmol), K2CO3 (0.41 g, 2.97 mmol), glycine methyl ester hydrochloride (0.27 g, 2.12 mmol) were added to 5 mL of acetonitrile and refluxed for 8 h. The mixture was cooled, concentrated under reduced pressure, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography [petroleum ether: ethyl acetate = 3:1 (V:V)] to obtain 0.15 g of a white solid with a yield of 41%. MS (EI) m / z 428 [MH] - ; 1HNMR(300MHz,Chloroform-d)δ8.05-7.98(m,2H),7.68-7.63(m,1H),7.51(s,1H),7.48(s,1H),7.45(s,1H),7.43(s,1H),7.36(t,J=6.9Hz,5H) , 4.24(s,2H),3.98(s,3H),3.77(s,2H),2.33(s,3H).

[0109] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,3,4-thiadiazol-2-yl)benzyl)glycine (1)

[0110] 1m (0.15 g, 0.36 mmol) and LiOH (25 mg, 1.05 mmol) were added to 3 mL of methanol and reacted at room temperature for 5 h. The solvent was removed by vortexing, 2 mL of water was added, the pH was adjusted to 3 with 4 M hydrochloric acid, filtered and dried to obtain 135 mg of a white solid with a yield of 92%. MS (ESI) m / z 416 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ8.08(d,J=7.5Hz,2H),7.79(d,J=7.8Hz,2H),7.70(d,J= 6.6Hz,1H),7.44(dd,J=11.4,8.1Hz,7H),4.13(s,2H),3.65(s,2H),2.30(s,3H).

[0111] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,3,4-thiadiazol-2-yl)benzyl)glycine hydrochloride (1s)

[0112] 1 (32 mg, 0.078 mmol) was added to 1 mL 4M 1,4-dioxane hydrochloric acid solution, stirred at room temperature overnight, concentrated under reduced pressure, washed with anhydrous ether, filtered and dried to obtain 27 mg of a white solid with a yield of 93%. MS (ESI) m / z 416 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.36(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,1H),7.80(s,1H),7. 70(s,1H),7.47(q,J=8.1,7.8Hz,5H),7.37(d,J=6.6Hz,3H),4.21(s,2H),3.75(s,2H),2.23(s,3H).

[0113] The following compounds were obtained by similar operation as in Example 1:

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124] Example 2: Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-4H-1,2,4-triazol-3-yl)benzyl)glycine (60) and its hydrochloride (60s)

[0125]

[0126] Synthesis of methyl 3-carbamoylbenzoate hydrochloride (2A)

[0127] Dissolve methyl 3-cyanobenzoate (7.50 g, 46.54 mmol) in 80 mL of methanol, add sodium methoxide (2.77 g, 51.19 mmol), react at 40°C for 12 h, then add ammonium chloride (4.98 g, 93.08 mmol), react at 50°C overnight. Cool, filter, spin-dry the filtrate, recrystallize with PE:EA=5:1, filter, and dry to obtain 6.90 g of a white solid, with a yield of 69%. MS (EI) m / z179[M+H] + ; 1 HNMR(300MHz,Chloroform-d)δ7.95(d,J=6.9Hz,1H),7.52(d,J=6.9Hz,1H),7.39-7.35(m,2H)3.87(s,3H).

[0128] Synthesis of methyl 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-4H-1,2,4-triazol-3-yl)benzoate (2B)

[0129] Add 2A (3.50 g, 16.31 mmol) and sodium methoxide (1.17 g, 21.74 mmol) to 20 mL of anhydrous ethanol, react at room temperature for 1 h, filter with suction, add 1C (2.46 g, 10.87 mmol) to the filtrate, reflux and stir overnight. Cool, filter with suction, extract with ethyl acetate, dry with anhydrous sodium sulfate, and purify with column chromatography [petroleum ether: ethyl acetate = 20:1 (V:V)] to obtain 2.61 g of a white solid with a yield of 65%. MS (ESI) m / z 370 [M+H] + ; 1 HNMR(300MHz,Chloroform-d)δ8.77(s,1H),8.37(d,J=7.8Hz,1H),8.23(d,J=7.8Hz,1H), 8.02(d,J=6.6Hz,1H),7.64(t,J=7.8Hz,1H),7.51-7.30(m,7H),3.99(s,3H),2.61(s,3H).

[0130] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-4H-1,2,4-triazol-3-yl)phenyl)methanol (2C)

[0131] 2B (2.62 g, 7.04 mmol) was added to 30 mL of anhydrous THF, and LiAlH4 (0.41 g, 10.56 mmol) was added under ice bath cooling, and the reaction was continued for 4 h. 40 mL of ice water was added, and the mixture was filtered and dried to obtain 2.21 g of a white solid with a yield of 94%. MS (ESI) m / z 342 [M+H] + ; 1 HNMR(300MHz,Chloroform-d)δ8.37(s,1H),8.18(d,J=7.8Hz,1H),8.12(dd,J=7.5,1.8Hz,1H ),7.83(d,J=7.8Hz,1H),7.70(t,J=7.8Hz,1H),7.56-7.35(m,7H),4.54(s,2H),2.33(s,3H).

[0132] Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-4H-1,2,4-triazol-3-yl)benzaldehyde (2D)

[0133] 2C (2.20 g, 6.44 mmol) was dissolved in 35 mL DMSO, and IBX (2.71 g, 9.67 mmol) was added. The mixture was reacted at room temperature for 2 h. The mixture was extracted with ethyl acetate and purified by column chromatography [petroleum ether: ethyl acetate = 20:1 (V:V)] to obtain 1.40 g of a white solid with a yield of 60%. MS (ESI) m / z 340 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ9.85(s,1H),8.37(s,1H),8.15(d,J=7.8Hz,1H),8.07(dd,J=7.5 ,1.8Hz,1H),7.81(d,J=7.8Hz,1H),7.68(t,J=7.8Hz,1H),7.62-7.32(m,7H),2.54(s,3H).

[0134] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-4H-1,2,4-triazol-3-yl)benzyl)glycine methyl ester (60m)

[0135] 2D (0.15 g, 0.44 mmol) was added to 5 mL DMF, followed by glycine methyl ester hydrochloride (0.14 g, 0.89 mmol), TEA (0.13 g, 1.33 mmol), glacial acetic acid (0.13 g, 2.21 mmol) and sodium cyanoborohydride (0.14 g, 2.21 mmol), reacted at room temperature for 4 h, added 10 mL of water, extracted with ethyl acetate, purified by column chromatography [petroleum ether: ethyl acetate = 1:1 (V:V)], and obtained 0.12 g of a white solid with a yield of 60%. MS (ESI) m / z 413 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.05-7.98(m,2H),7.68-7.63(m,1H),7.51(s,1H),7.48(s,1H),7.45(s,1H),7.43(s,1H),7.36(t,J=6.9Hz,5H) , 4.24(s,2H),3.98(s,3H),3.77(s,2H),2.33(s,3H).

[0136] Synthesis of compound 60 and its hydrochloride (60s)

[0137] Referring to the method of Example 1, 60m was hydrolyzed to obtain white solid 60 with a yield of 60%. 60 was then salified with hydrochloric acid to obtain white solid 60s with a yield of 94%. MS (ESI) m / z 399 [M+H] + ; 1HNMR(300MHz,DMSO-d6)δ8.93(s,1H),8.86(s,1H),8.36(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,1H),7.80(s,1H),7 .70(s,1H),7.47(q,J=8.1,7.8Hz,5H),7.37(d,J=6.6Hz,3H),4.21(s,2H),3.88(d,J=12.3Hz,2H),3.74(s,1H),2.23(s,3H).

[0138] Using similar operations as in Example 2, the following compounds were obtained:

[0139]

[0140]

[0141]

[0142] Example 3: Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)glycine (72) and its hydrochloride (72s)

[0143]

[0144] Synthesis of 3-(N-hydroxycarbamoyl)benzoic acid methyl ester (3A)

[0145] Dissolve methyl m-cyanobenzoate (2.61 g, 16.01 mmol) in 30 mL of anhydrous ethanol, add hydroxylamine hydrochloride (3.91 g, 56.02 mmol) and sodium bicarbonate (5.30 g, 64.02 mmol) in sequence under stirring, and reflux for 12 hours. Cool, filter, extract with ethyl acetate, dry with anhydrous sodium sulfate, and purify with column chromatography (PE:EA=15:1) to obtain 2.53 g of white solid, with a yield of 80%. MS (ESI) m / z195[M+H] + ; 1 H-NMR (300MHz, DMSO-d6): δ (ppm) 8.76-8.68 (m, 2H), 8.49 (s, 1H), 7.89 (s, 1H), 7.28 (s, 1H), 6.90 (s, 1H), 6.68 (s, 1H), 3.98 (s, 3H).

[0146] Synthesis of methyl 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)benzoate (3B)

[0147] 1A (4.80 g, 22.71 mmol), 1-hydroxybenzotriazole (3.31 g, 24.82 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.81 g, 24.80 mmol) and potassium carbonate (3.41 g, 24.80 mmol) were dissolved in 50 mL of DMF, stirred at room temperature for 0.5 h, and intermediate 3A (4.01 g, 20.62 mmol) was added, and the mixture was reacted at 110°C for 12 h under N2 protection. The mixture was cooled, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography (PE:EA=20:1) to obtain 3.51 g of a white solid with a yield of 46%. MS (ESI) m / z 371 [M+H] + ; 1 HNMR(300MHz,Chloroform-d)δ8.86(s,1H),8.39(d,J=7.8Hz,1H),8.22(d,J=8.0Hz,1H),8.12(dd,J=7 .5,1.8Hz,1H),7.62(t,J=7.8Hz,2H),7.52-7.39(m,5H),7.38-7.33(m,1H),3.99(s,3H),2.63(s,3H).

[0148] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (3C)

[0149] Referring to the method of Example 2, intermediate 3B was reduced with LiAlH4 to obtain white solid 3C with a yield of 81%. MS (ESI) m / z 343 [M+H] + ; 1 HNMR(300MHz,Chloroform-d)δ8.16(dd,J=7.1,4.2Hz,2H),8.04-7.98(m,1H),7.62-7.55(m ,2H),7.45(dt,J=9.8,4.3Hz,5H),7.39-7.34(m,2H),4.85(s,1H),4.84(s,2H),2.62(s,3H).

[0150] Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde (3D)

[0151] Referring to the method of Example 2, the intermediate 3C was reacted with IBX to obtain a white solid 3D with a yield of 80%. MS (ESI) m / z 341 [M+H] + ; 1HNMR (300MHz, Chloroform-d) δ10.12(s,1H),8.20(s,3H),8.02(d,J=7.0Hz,1H),7.45(t,J=6.9Hz,5H),7.36(d,J=6.6Hz,2H),3.99(s,3H),2.63(s,3H).

[0152] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)glycine methyl ester (72m)

[0153] Referring to the method of Example 2, the intermediate 3E and glycine methyl ester hydrochloride were subjected to reductive amination reaction to obtain a white solid 72m with a yield of 69%. MS (ESI) m / z 414 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.16(d,J=7.2Hz,2H),8.09(s,1H),7.78(d,J=7.1Hz,2H),7.54(s,2H ),7.52-7.46(m,3H),7.40(d,J=6.4Hz,2H),4.26(s,2H),3.9(s,3H),3.83(s,2H),2.54(s,3H).

[0154] Synthesis of compound 72 and its hydrochloride (72s)

[0155] Referring to the method of Example 1, 72m was hydrolyzed to obtain white solid 72 with a yield of 61%. 72 was then salified with hydrochloric acid to obtain white solid 72s with a yield of 93%. MS (ESI) m / z 400 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ9.54(s,1H),8.16(d,J=7.2Hz,2H),8.09(s,1H),7.78(d,J=7.1Hz,2H) ,7.54(s,2H),7.52-7.46(m,3H),7.40(d,J=6.4Hz,2H),4.26(s,2H),3.83(s,2H),2.54(s,3H).

[0156] The following compounds were obtained by similar operation as in Example 3:

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170] Example 4: Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-2-yl)benzyl)glycine (146) and its hydrochloride (146s)

[0171]

[0172] 1-(3-Bromo-2-methylphenyl)ethan-1-one (4A)

[0173] Dissolve 1,3-dibromo-2-methylbenzene (10.01 g, 40.01 mmol) in 85 mL of DMF, add tributyl (1-ethoxyethylene) tin (14.41 g, 40.01 mmol) and Pd (PPh3) 4 (0.46 g, 0.40 mmol) under stirring, and react at 85 ° C for 12 h under nitrogen protection. Cool, extract with ethyl acetate, and concentrate under reduced pressure. Add 20 mL of 4M HCl and react at room temperature for 3 h. Extract with ethyl acetate, dry with anhydrous sodium sulfate, and purify with column chromatography [petroleum ether: ethyl acetate = 15: 1 (V: V)] to obtain 8.04 g of oil, with a yield of 94%. MS (EI) m / z 213 [M + H] + ; 1 HNMR(300MHz,Chloroform-d)δ7.59(d,J=7.8Hz,1H),6.93(s,2H),2.60(s,3H),2.30(s,3H).

[0174] Synthesis of 1-(2-methyl-[1,1'-biphenyl]-3-yl)ethan-1-one (4B)

[0175] Referring to the method of Example 1, 4A and phenylboronic acid were coupled to obtain oily product 4B with a yield of 87%. MS (EI) m / z 211 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ7.70(dd,J=7.2,2.4Hz,1H),7.50-7.26(m,7H),2.58(d,J=2.7Hz,3H),2.22(d,J=3.0Hz,3H).

[0176] Synthesis of 2-bromo-1-(2-methyl-1,1'-biphenyl)-3-yl)ethan-1-one (4C)

[0177] 4B (1.50 g, 7.13 mmol) and copper bromide (3.51 g, 3.51 g) were added to 20 mL of ethyl acetate and refluxed for 8 h. Cooled, filtered, and concentrated under reduced pressure. 10 mL of tetrahydrofuran, diethyl phosphite (0.26 g, 1.87 mmol) and triethylamine (0.21 g, 2.06 mmol) were added and reacted at room temperature for 2 h. Extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography [petroleum ether: ethyl acetate = 20:1 (V:V)] to obtain 1.36 g of a white solid with a yield of 65%. MS (EI) m / z 289 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ7.80 (dd, J = 6.3, 2.7Hz, 1H), 7.50-7.36 (m, 5H), 7.35-7.26 (m, 2H), 4.91 (s, 2H), 2.21 (s, 3H).

[0178] Synthesis of 2-amino-1-(2-methyl-[1,1'-biphenyl]-3-yl)ethan-1-one (4D)

[0179] 4C (1.21 g, 4.15 mmol) and sodium diformamide (0.39 g, 4.15 mmol) were added to 15 mL of acetonitrile, reacted at 75 °C for 12 h, filtered while hot, concentrated under reduced pressure, added 5 mL of 4M HCl, and refluxed for 1 h. Concentrated under reduced pressure, recrystallized from ethyl acetate, and a white solid of 0.65 g was obtained, with a yield of 70%. MS (EI) m / z 226 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ8.39 (s, 3H), 7.90-7.84 (m, 1H), 7.53-7.39 (m, 6H), 4.52 (d, J = 6.0Hz, 2H), 2.28 (s, 3H).

[0180] Synthesis of methyl 3-(2-(2-methyl-[1,1'-biphenyl]-3-yl)-2-oxoethyl)carbamoyl)benzoate (4E)

[0181] Referring to the method of Example 1, 3-(methoxycarbonyl)benzoic acid and 4D were subjected to acylation reaction to obtain white solid 4E with a yield of 61%. MS (EI) m / z 388 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ9.21(s,1H),8.16-7.98(m,4H),7.75(d,J=8.1Hz,1H),7.53-7.31(m,6H),4.61(d,J=5.7Hz,2H),3.89(s,3H),2.22(s,3H).

[0182] Synthesis of methyl 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-2-yl)benzoate (4F)

[0183] 4E (0.20 g, 0.51 mmol) was added to 3 mL of acetic anhydride, and 4 drops of concentrated sulfuric acid were added. The mixture was reacted at 80°C for 2 h. The mixture was cooled, extracted with ethyl acetate, and concentrated under reduced pressure to obtain a white solid 4F with a yield of 62%. MS (EI) m / z 370 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ8.35-8.09(m,4H),7.95-7.70(m,2H),7.45(ddt,J=26.4,19.2,9.6Hz,7H),3.91(d,J=7.5Hz,3H),2.36(s,3H).

[0184] Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-2-yl)phenylmethanol (4G)

[0185] Referring to the method of Example 2, 4F and LiAlH4 were subjected to reduction reaction to obtain white solid 4G with a yield of 79%. MS (EI) m / z 342 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59 (m,1H),7.59-7.34(m,8H),7.29(s,1H),5.36(s,1H),4.59(s,2H),2.35(s,3H).

[0186] Synthesis of 2-(3-chloromethyl)phenyl-5-(2-methyl-[1,1'-biphenyl]-3-yl)oxazole(4H)

[0187] 4G (0.60 g, 1.76 mmol) was added to 5 mL of dichloromethane, and 0.3 mL of thionyl chloride was added dropwise under ice bath cooling, and the reaction was carried out at room temperature for 3 h. The mixture was extracted with ethyl acetate and concentrated under reduced pressure to obtain 0.53 g of a white solid with a yield of 83%. MS (EI) m / z 360 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),4.64(s,2H),2.33(s,3H).

[0188] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-2-yl)benzyl)glycine methyl ester (146m)

[0189] Referring to the method of Example 1, 4H and glycine methyl ester hydrochloride were subjected to condensation reaction to obtain white solid 146m with a yield of 58%. MS (EI) m / z 413 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.04(d,J=7.8Hz,2H),7.83(d,J=7.8Hz,1H),7.62(s,1H),7.57-7. 35(m,8H),7.29(dd,J=7.5,1.5Hz,1H),3.80(s,2H),3.64(s,3H),3.35(s,2H),2.36(s,3H).

[0190] Synthesis of Compound 146 and Its Hydrochloride (146m)

[0191] Referring to the method of Example 1, 146m was hydrolyzed to obtain 146 with a yield of 84%. 146 was then salified with hydrochloric acid to obtain 146s with a yield of 78%. MS (ESI) m / z 399 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.86(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,1H),7.80(s,1H),7. 70(s,1H),7.47(q,J=8.1,7.8Hz,5H),7.37(d,J=6.6Hz,4H),4.21(s,2H),3.75(s,2H),2.23(s,3H).

[0192] The following compounds were obtained by similar operation as in Example 4:

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203] Example 5: Synthesis of 3-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-4-yl)benzyl)glycine (199) and its hydrochloride (199s)

[0204] Synthesis of 2-methyl-[1,1'-biphenyl]-3-carboxamide (5A)

[0205] 1C (2.00 g, 9.42 mmol), ammonia (0.66 g, 18.85 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.37 g, 14.13 mmol), N,N-diisopropylethylamine (2.44 g, 18.85 mmol) were added to 80 mL of DMF and reacted at room temperature overnight. 200 mL of water was added, filtered and dried to obtain 1.63 g of a white solid with a yield of 82%. MS (EI) m / z 212 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ7.70 (dd, J=7.2, 2.4Hz, 1H), 7.50-7.26 (m, 7H), 2.22 (s, 3H).

[0206] Synthesis of methyl 3-(2-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-4-yl)benzoate (5B)

[0207] 5A was subjected to cyclization reaction to obtain white solid 5B in 53% yield. MS (EI) m / z 370 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.90(s,1H),8.44(s,1H),8.14(d,J=7.8Hz,1H),7.94(t,J=6.6Hz, 2H),7.63(t,J=7.8Hz,1H),7.52-7.44(m,3H),7.44-7.35(m,4H),3.89(s,3H),2.52(s,3H).

[0208] Synthesis of 3-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-4-yl)phenylmethanol (5C)

[0209] Referring to the method of Example 2, 5B and LiAlH4 were subjected to reduction reaction to obtain white solid 5C with a yield of 71%. MS (EI) m / z 342 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.91(s,1H),8.42(s,1H),8.14(d,J=7.8Hz,1H),7.94(t,J=6.6Hz, 2H),7.63(t,J=7.8Hz,1H),7.52-7.44(m,3H),7.45-7.34(m,4H),5.27(s,2H),2.52(s,3H).

[0210] Synthesis of 4-(3-chloromethyl)phenyl-2-(2-methyl-[1,1'-biphenyl]-3-yl)oxazole (5D)

[0211] Referring to the method of Example 4, 5C was reacted to obtain white solid 5D with a yield of 83%. MS (EI) m / z 360 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.91(s,1H),8.42(s,1H),8.14(d,J=7.8Hz,1H),7.94(t,J=6.6Hz, 2H),7.63(t,J=7.8Hz,1H),7.52-7.44(m,3H),7.45-7.34(m,4H),5.27(s,2H),2.52(s,3H).

[0212] Synthesis of 3-(2-methyl-[1,1'-biphenyl]-3-yl)oxazol-4-yl)benzyl)glycine methyl ester (199m)

[0213] Referring to the method of Example 1, 5D and glycine methyl ester hydrochloride were reacted to obtain white solid 199m with a yield of 80%. MS (EI) m / z 413 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.77(s,1H),8.08(s,1H),7.92(dd,J=10.9,6.1Hz,2H),7.53(d,J=4.8Hz,2H),7.51-7.44(m,3H) ,7.43(s,1H),7.39(d,J=3.3Hz,2H),7.36(s,1H),3.82(t,J=9.3Hz,2H),3.62(d,J=7.2Hz,2H),3.89(s,3H),2.35(s,3H).

[0214] Synthesis of Compound 199 and Its Hydrochloride (199s)

[0215] Referring to the method of Example 1, 199m was hydrolyzed to obtain white solid 199 with a yield of 58%. 199 was then salified with hydrochloric acid to obtain white solid 199s with a yield of 88%. MS (ESI) m / z 399 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ9.02(s,1H),8.36(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,2 H),7.47(q,J=8.1,7.8Hz,6H),7.37(d,J=6.6Hz,3H),4.21(s,2H),3.75(s,2H),2.23(s,3H).

[0216] Using similar operations as in Example 5, the following compounds were obtained:

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223] Example 6: Synthesis of (3-[4-(2-methyl-[1,1'-biphenyl]-3-yl])-1H-imidazol-2-yl)benzyl)-L-alanine (227) and its hydrochloride (227s)

[0224]

[0225] Synthesis of methyl 3-(4-(2-methyl-[1,1'-biphenyl]-3-yl))-1H-imidazol-2-yl)benzoate (6A)

[0226] 2A (2.00 g, 9.23 mmol) and K2CO3 (1.93 g, 13.98 mmol) were added to 20 mL tetrahydrofuran and 5 mL water, stirred for 0.5 h, and 4C (2.42 g, 8.39 mmol) was added, and the mixture was reacted at 70°C for 6 h. The mixture was cooled, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography [petroleum ether:ethyl acetate = 4:1 (V:V)] to obtain 1.06 g of a yellow oil with a yield of 52%. MS (EI) m / z 367 [MH] - ; 1 HNMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),3.89(s,3H),2.35(s,3H).

[0227] Synthesis of (3-[4-(2-methyl-[1,1'-biphenyl]-3-yl])-1H-imidazol-2-yl)phenyl)methanol (6B)

[0228] Referring to the method of Example 2, 6A was reacted with LiAlH4 to obtain yellow oil 6B with a yield of 94%. MS (EI) m / z 339 [MH] - ; 1 HNMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),4.59(s,2H),2.35(s,3H).

[0229] Synthesis of 2-(3-(chloromethyl)phenyl)-4-(2-methyl-[1,1'-biphenyl]-3-yl)-1H-imidazole (6C)

[0230] Referring to the method of Example 4, 6B was reacted to obtain yellow oil 6C with a yield of 97%. MS (EI) m / z 357 [MH]- ; 1 H NMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),4.64(s,2H),2.33(s,3H).

[0231] Synthesis of (3-[4-(2-methyl-[1,1'-biphenyl]-3-yl])-1H-imidazol-2-yl)benzyl)-L-alanine methyl ester (227m)

[0232] Referring to the method of Example 1, 6C and L-alanine methyl ester hydrochloride were reacted to obtain a yellow oil 227m with a yield of 63%. MS (EI) m / z 425 [MH] - ; 1 HNMR (300MHz, DMSO-d6) δ8.43(s,1H),8.31(d,J=7.8Hz,1H),7.95(s,1H),7.88(d,J=7.8Hz,1H),7.73(t,J=7.8Hz,1H),7 .63(dd,J=7.8,1.5Hz,1H),7.55-7.29(m,7H),3.92(s,3H),3.57(s,2H),3.39(s,1H),2.30(s,3H),1.57(d,J=7.2Hz,3H).

[0233] Synthesis of Compound 227 and Its Hydrochloride (227s)

[0234] Referring to the method of Example 1, 227m was hydrolyzed to obtain white solid 227 with a yield of 80%. 227 was then salified with hydrochloric acid to obtain white solid 227s with a yield of 88%. MS (ESI) m / z 413 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ8.36(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,2H),7.80(s,1H),7.70(s,1H),7.4 7(q,J=8.1,7.8Hz,5H),7.37(d,J=6.6Hz,3H),4.21(s,2H),3.75-3.65(m,1H),2.23(s,3H),1.53(d,J=4.3Hz,3H).

[0235] Using similar operations as in Example 6, the following compounds were obtained:

[0236]

[0237]

[0238] Example 7: Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiazol-2-yl)benzyl)glycine (235) and its hydrochloride (235s)

[0239]

[0240] Synthesis of methyl 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiazol-2-yl)benzoate (7A)

[0241] Referring to the method of Example 1, 4E and Lawesson's reagent were subjected to cyclization reaction to obtain white solid 7A with a yield of 83%. MS (EI) m / z 384 [MH] - ; 1 HNMR(300MHz,Chloroform-d)δ8.11(s,1H),8.01(dt,J=6.9,1.8Hz,1H),7.68(dd,J=6.6,2.4Hz,1H),7.56(s,1H),7.48(s,1 H),7.46(s,1H),7.43(s,1H),7.41(d,J=2.7Hz,2H),7.39(d,J=1.8Hz,2H),7.36(t,J=1.5Hz,2H),3.90(s,3H),2.46(s,3H).

[0242] Synthesis of 3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiazol-2-yl)phenylmethanol (7B)

[0243] Referring to the method of Example 2, 7A was reacted with LiAlH4 to obtain white solid 7B with a yield of 94%. MS (EI) m / z 356 [MH] - ; 1 HNMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),4.59(s,2H),2.35(s,3H).

[0244] Synthesis of 2-(3-chloromethyl)phenyl-5-(2-methyl-[1,1'-biphenyl]-3-yl)thiazole (7C)

[0245] Referring to the method of Example 4, 7B was reacted to obtain white solid 7C with a yield of 95%. MS (EI) m / z 374 [MH] - ; 1 HNMR (300MHz, DMSO-d6) δ8.18-8.02(m,2H),7.83(d,J=10.5Hz,1H),7.72-7.59(m,1H),7.59-7.34(m,8H),7.29(s,1H),4.64(s,2H),2.33(s,3H).

[0246] Synthesis of (3-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiazol-2-yl)benzyl)glycine methyl ester (235m)

[0247] Referring to the method of Example 1, 7C was reacted with glycine methyl ester hydrochloride to obtain a white solid 235m with a yield of 76%. MS (EI) m / z 427 [MH] - ; 1 HNMR(300MHz,DMSO-d6)δ8.04(d,J=7.8Hz,2H),7.83(d,J=7.8Hz,1H),7.62(s,1H),7.57-7. 35(m,8H),7.29(dd,J=7.5,1.5Hz,1H),3.80(s,2H),3.64(s,3H),3.35(s,2H),2.36(s,3H).

[0248] Synthesis of Compound 235 and Its Hydrochloride (235s)

[0249] Referring to the method of Example 1, 235m was hydrolyzed to obtain white solid 235 with a yield of 87%. 235 was then salified with hydrochloric acid to obtain white solid 235s with a yield of 90%. MS (ESI) m / z 415 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ9.02(s,1H),8.36(s,1H),8.15(d,J=7.2Hz,1H),8.05(d,J=6.9Hz,2H),7.80(s,1 H),7.70(s,1H),7.47(q,J=8.1,7.8Hz,5H),7.37(d,J=6.6Hz,2H),4.21(s,2H),3.75(s,2H),2.23(s,3H).

[0250] Using similar operations as in Example 7, the following compounds were obtained:

[0251]

[0252]

[0253]

[0254] Example 8: Synthesis of (4-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiophen-2-yl)benzyl)glycine (245) and its hydrochloride (245s)

[0255]

[0256] Synthesis of 2-(3-bromo-2-methylphenyl)thiophene (8A)

[0257] Referring to the synthesis of Example 1, 2,5-dibromotoluene and 2-boronic acid thiophene were used as raw materials to obtain a light yellow oily liquid 8A with a yield of 89%, which was directly used in the next step reaction.

[0258] Synthesis of 2-(2-methyl-[1,1'-biphenyl]-3-yl)thiophene (8B)

[0259] Referring to the synthesis of Example 1, 8A and phenylboronic acid were coupled to obtain yellow oily liquid 8B with a yield of 82%, which was directly used in the next step reaction.

[0260] Synthesis of 2-bromo-5-(2-methyl-[1,1'-biphenyl]-3-yl)thiophene (8C)

[0261] 8B (2.20 g, 8.79 mmol) was dissolved in 5 mL DMSO, and N-bromosuccinimide (1.56 g, 8.79 mmol) was added. The mixture was reacted at room temperature for 3 h. After the reaction was completed, 50 mL of water was added, the mixture was filtered and dried to obtain 2.62 g of a light yellow solid with a yield of 90%, which was directly used for the next step.

[0262] Synthesis of 4-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiophen-2-yl)benzaldehyde (8D)

[0263] 8C (2.62 g, 7.91 mol) was dissolved in 20 mL of dioxane, and then 2 mL of water, 4-formylphenylboronic acid pinacol ester (2.38 g, 10.3 mol), potassium carbonate (3.27 g, 23.7 mmol), and Pd(dppf)Cl2 (32 mg, 0.04 mmol) were added in sequence. The mixture was reacted at 80°C for 8 h under nitrogen. The mixture was cooled, the solvent was removed by rotation, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography (petroleum ether: ethyl acetate = 5:1 (V:V)) to obtain 1.61 g of a light yellow solid with a yield of 57%, which was directly used for the next step.

[0264] Synthesis of (4-(5-(2-methyl-[1,1'-biphenyl]-3-yl)thiophen-2-yl)benzyl)glycine methyl ester (245m)

[0265] Referring to the method of Example 2, 8D and glycine methyl ester hydrochloride were subjected to reductive amination reaction to obtain a light yellow solid 245m with a yield of 59%. MS (ESI) m / z 428 [M+H] + ; 1 HNMR (300MHz, DMSO-d6) δ7.76(d,J=8.1Hz,2H),7.62(d,J=3.6Hz,1H),7.57(d,J=8.1Hz,3H),7.52-7. 40(m,3H),7.40-7.33(m,3H),7.28-7.21(m,2H),4.18(s,2H),3.91(s,3H),3.83(s,2H),2.27(s,3H).

[0266] Synthesis of Compound 245 and Its Hydrochloride (245s)

[0267] Referring to the method of Example 1, 245m was hydrolyzed to obtain yellow solid 245 with a yield of 85%. 245 was then salified with hydrochloric acid to obtain light yellow solid 245s with a yield of 96%. MS (ESI) m / z 414 [M+H] + ; 1 HNMR(300MHz,DMSO-d6)δ7.76(d,J=8.1Hz,2H),7.62(d,J=3.6Hz,1H),7.57(d,J=8.1Hz,2H),7 .52-7.40(m,4H),7.40-7.33(m,3H),7.28-7.21(m,2H),4.18(s,2H),3.83(s,2H),2.27(s,3H).

[0268] Using similar operations as in Example 8, the following compounds were obtained:

[0269]

[0270]

[0271]

[0272]

[0273]

[0274] Example 9: Evaluation of pharmacological activity

[0275] 1. Inhibitory activity of the compounds of the present invention on PD-1 / PD-L1 protein-protein interaction

[0276] 1.1 Experimental Purpose

[0277] The PD-1 / PD-L1 binding assay kit (BPS Bioscience) was used to detect the inhibitory activity of the compounds of the present invention on PD-1 / PD-L1 protein-protein interaction.

[0278] 1.2 Main experimental materials

[0279] The PD-1 / PD-L1 binding assay kit was purchased from BPS Bioscience, which contains reagents required for the experiment, such as PD-1, PD-L1, Anti-tag1-Eu, Anti-tag2-XL665, Dilute Buffer and Detection Buffer; the 384-well microplate was purchased from PerkinElmer; and the positive drug (BMS-202) was purchased from Selleck.

[0280] 1.3 Instruments

[0281] Centrifuge (Eppendorf, model: 5430); Microplate reader (PerkinElmer, model: EnVision)

[0282] 1.4 Experimental methods

[0283] (1) Prepare 1× Assay buffer.

[0284] (2) Compound loading: Use the Echo550 instrument to transfer 200 nL of compound into a 384-well reaction plate according to different compound concentration gradients.

[0285] (3) Prepare PD-L1-Biotin working solution in 1×Assay buffer.

[0286] (4) Add 5 μL of PD-L1-Biotin working solution to the compound wells and positive control wells respectively; add 5 μL of Assay buffer to the negative control wells.

[0287] (5) Centrifuge at 1000 rpm for 30 seconds and incubate at room temperature for 15 minutes.

[0288] (6) Prepare a mixture of PD-1-Eu and Dyelabeled acceptor in 1×Assay buffer.

[0289] (7) Add 15 μL of PD-1-Eu and Dyelabeled acceptor mixture.

[0290] (8) Centrifuge at 1000 rpm for 30 seconds and incubate at room temperature for 90 minutes.

[0291] (9) EnVision reads the 665nm / 615nm ratio. The inhibition rate of the compound on protein binding is calculated based on the fluorescence ratio.

[0292] 1.5 Data formula

[0293]

[0294] Where: Ratio sample is the ratio of the sample wells; Ratio min : Mean value of negative control well ratio; Ratio max : The average value of the positive control well ratio, and the compound IC was calculated using Graphpad 50 value.

[0295] 1.6 Experimental Results

[0296] The inhibitory activity of the compounds of the present invention on PD-1 / PD-L protein-protein interaction is shown in Table 1. The experimental results show that the compounds of the present invention have significant inhibitory activity on PD-1 / PD-L1 protein-protein interaction. Wherein, A represents IC 50 =1nM-100nM; B represents IC 50 =100.01nM-500nM; C represents IC 50 =500.01nM-20μM.

[0297] Table 1. Inhibitory activity of the compounds of the present invention on PD-1 / PD-L1 interaction

[0298]

[0299]

[0300]

[0301]

[0302] *Control group: BMS-1018 is compound No. 1018 in patent WO2015160641A2.

[0303] 2. Toxicity test of the compounds of the present invention on cells

[0304] In order to verify whether the compound of the present invention has obvious cytotoxicity, the MTT method was used to detect the effect of the compound of the present invention on the viability of Lewis lung cancer cells.

[0305] 2.1 Experimental methods

[0306] Add 20 μL of 4 mg / mL MTT solution to each well of a 96-well plate, place in a cell culture incubator and incubate for 4 hours. Centrifuge the 96-well plate, carefully remove the liquid in the well, add 200 μL of dimethyl sulfoxide to each well, place on a shaker and shake at 300 r for 10 minutes to fully dissolve the purple crystalline substance. Finally, detect the absorbance at 570 nm on an ELISA reader. Calculate the inhibition rate using the Bliss method based on the absorbance.

[0307]

[0308] 2.2 Experimental Results

[0309] The experimental results are as follows Figure 1 The results showed that compared with the model group, the compound 77 of the present invention had no significant effect on the viability of Lewis lung cancer cells at various tested concentrations, indicating that the compound of the present invention had no significant cytotoxicity.

[0310] 3. Effects of the compounds of the present invention on the release of cytokine INF-γ

[0311] Cytokines are a unique class of molecules with both effector and regulatory functions, and they play an important role in immunoregulatory responses in lymphocyte responses. Activated human peripheral blood mononuclear cells (PBMCs) can release cytokines such as IFN-γ, IL-2, and TNF-α, and when PD-1 expressed on the PBMC membrane binds to its ligand PD-L1, it will inhibit the release of cytokines. The purpose of this experiment is to detect whether the compounds of the present invention can reverse the ability of PD-1 / PD-L1 to inhibit the secretion of INF-γ by PBMCs.

[0312] 3.1 Experimental methods

[0313] Human peripheral blood mononuclear cells (PBMCs) were extracted using human lymphocyte separation fluid and inoculated into 24-well plates. Anti-CD3 / anti-CD28 with a final concentration of 1 g / mL, ligand protein with a final concentration of 2 g / mL, and different doses of compounds were added. After 48 hours, 100 L of supernatant was collected by centrifugation and the expression level of INF-γ in the supernatant was detected using the INF-γ enzyme-linked immunosorbent assay kit produced by Dakoway.

[0314] 3.2 Experimental Results

[0315] The experimental results are as follows Figure 2As shown. The results showed that compared with the model group, the addition of anti-CD3 / anti-CD28 significantly promoted the release of INF-γ, while the addition of PD-L1 significantly reduced the level of INF-γ, indicating that PD-1 / PD-L1 significantly inhibited the release of INF-γ. When different concentrations of the compound 77 of the present invention were added, the level of INF-γ was significantly increased in a dose-dependent manner, indicating that the compound of the present invention can block the inhibitory effect of PD-1 / PD-L1 on PBMC, thereby restoring the activity of T cells and promoting the secretion of INF-γ.

[0316] 4. Pharmacokinetics of the compounds of the present invention

[0317] Good pharmacokinetic properties are essential parameters for evaluating the drugability of a candidate drug. In order to test whether the compounds of the present invention have good drugability, the compound 77 of the present invention was selected to carry out pharmacokinetic experiments in rats, and BMS-1018 was a positive drug.

[0318] 4.1 Experimental methods

[0319] The animals selected for the experiment were SD rats weighing 200-250 grams. The dosages of compound 77 and BMS-1018 were 10 mg / kg orally and 2 mg / kg intravenously, respectively. There were 3 rats in the oral group and 5 rats in the intravenous group. Plasma samples were collected at 9 time points after administration to calculate the pharmacokinetic parameters.

[0320] On the day of the experiment, ICR male mice were randomly divided into groups according to body weight, with 3 mice in each group. The mice were fasted but not watered for 12-14 hours one day before administration, and were fed 4 hours after administration. 0.030 mL of blood was collected from each animal through the eye socket each time, and anticoagulated with EDTAK2. The collection time points were: (1) IG group: 0.0833, 0.25, 0.5, 1, 2, 4, 6, 8, 24 hours. (2) IV group: 0.25, 0.5, 1, 2, 4, 6, 8, 24 hours after administration of the test substance. After blood collection, the samples were placed on ice and centrifuged within 30 minutes to separate the plasma, which was stored at -80°C before analysis.

[0321] Take 10 μL of sample (take out the sample from the refrigerator at -80℃, dissolve it naturally at room temperature and then vortex for 30 seconds) into a 1.5mL centrifuge tube, add 100 μL of internal standard solution (5.0 ng / mL verapamil, 30.0 ng / mL buspirone and 60.0 ng / mL dexamethasone acetonitrile solution), vortex for 60 seconds and centrifuge for 3 minutes (12000 rpm); take 75 μL of the supernatant and transfer it to a 96-well injection plate filled with an equal volume of water, shake and mix well, and then perform LC-MS / MS injection analysis, with an injection volume of 10 μL.

[0322] The data acquisition and control system software was Analyst 1.5.1. The peak integration method of the chromatogram sample was automatic integration. The ratio of the sample peak area to the internal standard peak area was used as an indicator and regressed with the sample concentration. Regression method: linear regression, with a weight coefficient of 1 / X2. Pharmacokinetic parameters were analyzed and processed using WinNonlin Professional v6.3 (Pharsight, USA) using a non-compartmental model. C max is the maximum measured blood drug concentration, the area under the blood drug concentration-time curve AUC (0→t) Calculated by the trapezoidal method, T max It is the time when the blood drug concentration reaches the peak after administration.

[0323] 4.2 Experimental Results

[0324] The experimental results are shown in Table 2. As can be seen from the table, compound 77 has good pharmacokinetic parameters, especially it has a long half-life, and the oral bioavailability reaches 23.94%. It is worth mentioning that the blood concentration of BMS-1018 cannot be detected after oral administration, and its half-life of intravenous injection is only 0.53h. These experimental results show that the compounds of the present invention have good pharmacokinetic properties.

[0325] Table 2 Pharmacokinetic results in rats

[0326]

[0327] 5. In vivo pharmacodynamic evaluation of the compounds of the present invention

[0328] Proliferating cell nuclear antigen (PCNA) is a nuclear protein necessary for eukaryotic cell DNA synthesis. Detection of PCNA can objectively evaluate the proliferation status of tumor cells. To this end, in the process of in vivo pharmacodynamic evaluation, immunohistochemistry and TUNEL analysis were used to detect the infiltration of T lymphocytes in tumor tissues and the levels of IFN-γ and PCNA. BMS-1018 was used as the positive control group.

[0329] 5.1 Experimental Methods

[0330] Mice culture: Select 7-8 week old female mice and raise them in an SPF animal breeding room for one week. Each mouse weighs approximately 18-20 g.

[0331] Treatment of tumor cells: Tumor cells in the logarithmic growth phase were collected, centrifuged at 180 g for 5 min (4°C), washed twice with pre-cooled PBS, and pipetted evenly. The final cell concentration was 1×10 7 / mL, keep on ice until use.

[0332] Tumor cell transplantation: Lewis lung cancer cell suspension was inoculated subcutaneously into the right axilla of BALB / c female mice. The number of inoculated tumor cells was 1×10 6 / mouse. The tumor size of mice was measured with a vernier caliper every two days, and the mice were weighed once. When the mean tumor volume reached 40 mm 3 At about 3 pm, start administering the drug.

[0333] Experimental grouping and administration method: BALB / c female mice transplanted with Lewis lung cancer cells were divided into 4 groups, 6 mice in each group. Model group (solvent: PBS + 2% Tween 20 + 2% DMSO, intragastric administration, once a day), positive control group (BMS-1018, intragastric administration, once a day, dose: 15 mg / kg), drug treatment group 1 (compound 77, intragastric administration, once a day, dose: 5 mg / kg), drug treatment group 2 (compound 77, intragastric administration, once a day, dose: 15 mg / kg).

[0334] When the tumor volume reaches a certain size, the animal experiment is terminated. The mice are weighed, blood is collected from their eyeballs, and the mice are euthanized. The tumor tissues are removed, weighed, and photographed. At the same time, part of the tissue is placed in 10% neutral fixative, and the samples are sent for paraffin embedding, paraffin tissue sections are made, and H&E staining, TUNEL, and immunohistochemistry analysis are performed. The experimental operation refers to the instructions for the detection kit.

[0335] 5.2 Experimental Results

[0336] The experimental results are as follows Figure 3 The results showed that compared with the model group, the compound 77 of the present invention could significantly inhibit the growth of Lewis lung cancer transplanted tumors in mice at a dose of 5 mg / kg and 15 mg / kg, showing a dose-dependent effect, and did not affect the weight of the mice. In addition, at the same dosage, the inhibitory activity of compound 77 on transplanted tumors was significantly better than that of the control group BMS-1018, indicating that the compound of the present invention

[0337] The results of immunohistochemistry and TUNEL experiments showed that compared with the model group, compound 77 at doses of 5 mg / kg and 15 mg / kg could significantly promote the infiltration of T lymphocytes in tumor tissues, increase the level of IFN-γ, and reduce the expression of PCNA protein. Moreover, at a dose of 5 mg / kg, compound 77 was more effective in reversing the PD-1 / PD-L1-mediated immunosuppression than the BMS-1018 control group.

[0338] 6. Effects of the compounds of the present invention on T lymphocyte infiltration in the tumor microenvironment

[0339] T lymphocytes are the core executors of the human immune system and play an important role in tumor immune response. Tumor infiltrating lymphocytes (TIL) refer to white blood cells that leave the bloodstream and enter the tumor. When there are a large number of tumor infiltrating lymphocytes in the tumor microenvironment, it indicates that the body has initiated an immune response against the tumor. Activation of the PD-1 / PD-L1 signaling pathway inhibits the anti-tumor immune microenvironment, resulting in reduced lymphocyte infiltration. The purpose of this experiment is to analyze the effect of the compounds of the present invention on T lymphocyte infiltration in the tumor microenvironment.

[0340] 6.1 Experimental methods

[0341] Take part of the tumor tissue peeled in Experiment 4, cut it into pieces and transfer it to a 15 mL centrifuge tube, add collagenase IV (0.5 mg / mL) and DNase I (0.5 mg / mL), digest it at 37°C for 30 min, filter out the remaining tissue fragments, resuspend the cells by centrifugation, and use CD45, CD3, CD4, and CD8 flow cytometry antibodies of different channels to stain in the dark for 30 min, and detect it by flow cytometry.

[0342] 6.2 Experimental Results

[0343] The experimental results are as follows Figure 4 The results showed that compared with the model group, compound 77 at 5mg / kg and 15mg / kg doses could significantly promote CD45 + Leukocytes, CD45 + CD3 + T lymphocytes, CD8 + CD45 + CD3 + The infiltration of cytotoxic T cells was dose-dependent, while the effect on CD4 + CD45 + CD3 + The effect on regulatory T lymphocytes was weak. In addition, at the same dose, compound 77 was more potent than BMS-1018 in promoting lymphocyte infiltration, especially on CD45 + CD3 + CD8 + The increase in infiltration of cytotoxic T lymphocytes was more prominent. These experiments show that the compounds of the present invention can effectively reverse the immunosuppression mediated by PD-1 / PD-L1 and reshape the anti-tumor immune microenvironment.

[0344] It should be noted that other compounds in the present invention exhibit significant anti-tumor effects in mouse transplant tumor models of various tumor types such as CT26, EMT6, B16F1, PAN02, LLC, etc., and these compounds can promote the infiltration of lymphocytes into the tumor microenvironment, increase the secretion of IFN-γ in tumor tissues, and reduce the expression of PCNA protein. These experiments show that the compounds of the present invention can block the immunosuppression mediated by PD-1 / PD-L1 and activate anti-tumor immune response.

Claims

1. A phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof, characterized in that: The five-membered heterocyclic compound has a structure of formula I, in: The definitions of X, A, and B satisfy any of the following conditions: (1) When X is O and A is N, B is C; when X is O and A is C, B is N or C; (2) When X is S, A and B are N or C; (3) When X is NH, A is N, and B is N; (4) When X is N and A is N, B is O; when X is N and A is C, B is O or NH; when X is N and A is O, B is C or N; R 1 is selected from methyl, cyano, hydroxyl or halogen; R 2 is selected from hydrogen, halogen, nitro, cyano, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl; the C1-C4 alkyl is substituted by one or more W groups; W is selected from hydrogen, halogen, cyano, hydroxyl, mercapto, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino or C1-C6 haloalkyl; R 3 , R 4 Each is independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, C3-C8 cycloalkyl, 5-7 membered heterocyclyl or R 3 and R 4 Together with the nitrogen atom to which they are attached, they form a 5-7 membered heterocyclic group; the heterocyclic group may optionally contain one or more heteroatoms selected from O, S or N; the C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, C3-C8 cycloalkyl or 5-7 membered heterocyclic group is substituted by one or more Y groups; Y is selected from hydrogen, halogen, hydroxyl, mercapto, methylthio, formyl, carboxyl, amino, guanidinyl, furanyl, tetrahydropyrrolyl, morpholinyl, N-methylpiperazinyl, C1-C4 alkyl, -CO2R 5 、-NHCOR 5 、-NR 6 R 7 or-CONR 6 R 7 ; The C1-C4 alkyl group is substituted by one or more hydroxyl groups or halogen groups; R 5 Selected from C1-C8 alkyl; R 6 , R 7 Each independently selected from hydrogen, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or R 6 and R 7 Together with the nitrogen atom to which they are attached, they form a 5-7 membered heterocyclic group; the C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or 5-7 membered heterocyclic group is substituted by one or more Z groups; Z is selected from hydrogen, halogen, hydroxy, thiol, carboxyl, amino or acetamido.

2. A phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof, characterized in that: The five-membered heterocyclic compound has a structure of formula I, in: The definitions of X, A, and B satisfy any of the following conditions: (1) When X is O and A is N, B is C; when X is O and A is C, B is N or C; (2) When X is S, A and B are N or C; (3) When X is NH, A is N, and B is N; (4) When X is N and A is N, B is O; when X is N and A is C, B is O or NH; when X is N and A is O, B is C or N; R 1 is selected from methyl, cyano, hydroxyl or halogen; R 2 is selected from hydrogen, halogen, nitro, cyano, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl; the C1-C4 alkyl is substituted by one or more W groups; W is selected from hydrogen, halogen, cyano, hydroxyl, mercapto, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino or C1-C6 haloalkyl; Selected from the following groups:

3. The phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: In the structure: R 1 is selected from methyl or halogen; R 2 is selected from hydrogen, nitro or halogen; R 3 , R 4 Each independently selected from hydrogen, C1-C5 alkyl or R 3 and R 4 Together with the nitrogen atom to which they are connected, they form a 5-6 membered N-containing heterocyclic group; the C1-C5 alkyl group or the 5-6 membered heterocyclic group is substituted by one or more Y groups; Y is selected from hydrogen, hydroxy, formyl, carboxyl, guanidinyl, C1-C4 alkyl, -CO2R 5 、-NR 6 R 7 or-CONR 6 R 7 ; The C1-C4 alkyl group is substituted with one or more hydroxyl groups; R 5 Selected from C1-C4 alkyl; R 6 , R 7 Each is independently selected from hydrogen or C1-C4 alkyl.

4. The phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: In the structure: R 1 is selected from methyl or chlorine; R 2 is selected from hydrogen, nitro, fluorine, chlorine or bromine; R 3 , R 4 Each independently selected from hydrogen, C1-C5 alkyl or R 3 and R 4 Together with the nitrogen atom to which they are connected, they form a 5-6 membered heterocyclic group containing one N atom; the C1-C5 alkyl group or the 5-6 membered heterocyclic group is substituted by one or more Y groups; Y is selected from hydrogen, hydroxy, formyl, carboxyl, guanidino, C1-C4 alkyl, -CO2CH3, amino or -CONH2; the C1-C4 alkyl is substituted by one or more hydroxyl groups.

5. The phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: In the structure: Select from the following ring systems:

6. A phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof, characterized in that: The five-membered heterocyclic compound is selected from any of the following compounds:

7. A method for preparing a phenyl and biphenyl substituted five-membered heterocyclic compound according to any one of claims 1 to 5, characterized in that: Choose from any of the following methods: Method 1: When X is S, A and B are N, compound a-1 is used as a raw material to obtain a compound of formula (I) through Suzuki coupling, esterification, hydrazinolysis, condensation, cyclization, condensation reaction, or further through alkaline hydrolysis to obtain a compound of formula (I); Method 2: When X is NH, A and B are N, compound d-1 is subjected to cyclization, reduction, oxidation, and reductive amination to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 3: When X is N, A is O, and B is N, compound a-2 is subjected to addition, cyclization, reduction, oxidation, and reductive amination to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 4: When X and A are N, and B is O, compound a-3 is subjected to Suzuki coupling, addition, condensation, reduction, oxidation, reductive amination reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I); Method 5: When X is O, A is C, and B is N, compound a-4 is subjected to coupling, Suzuki coupling, bromination, and amination to obtain intermediate d-5, and intermediate d-5 is subjected to condensation, cyclization, reduction, halogenation, and condensation to obtain the compound of general formula (I), or further subjected to alkaline hydrolysis to obtain the compound of general formula (I); Alternatively, the intermediate d-5 is subjected to condensation and cyclization reaction to obtain the compound of general formula (I), or is further subjected to alkaline hydrolysis to obtain the compound of general formula (I); Method 6: When X is O, A is N, and B is C, compound b-1 is subjected to chlorination, condensation, cyclization, reduction, halogenation, condensation reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I); Method 7: When X is N, A is O, and B is C, compound b-1 is subjected to amination, cyclization, reduction, halogenation, and condensation to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 8: When X is N, A is C, and B is O, compound c-5 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 9: When X is N, A is C, and B is NH, compound c-5 is subjected to cyclization, reduction, halogenation, and condensation reaction to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 10: When X is S, A is C, and B is N, compound e-5-1 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 11: When X is S, A is N, and B is C, compound c-6 is subjected to cyclization, reduction, halogenation, and condensation reactions to obtain a compound of formula (I), or further subjected to alkaline hydrolysis to obtain a compound of formula (I); Method 12: When X is S or O, and A and B are C, compound a-4 is subjected to coupling, coupling, bromination, Suzuki coupling, reductive amination reaction to obtain the compound of formula (I), or further subjected to alkaline hydrolysis to obtain the compound of formula (I); Among them, R 1 , R 2 , R 3 , R 4 The definition is as described in any one of claims 1-5.

8. Use of a phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 in the preparation of a PD-L1 inhibitor drug.

9. Use of a phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 in the preparation of an immunomodulatory drug.

10. The use according to claim 9, characterized in that: The immunomodulator drugs are drugs for preventing and / or treating tumors, infectious diseases, inflammatory diseases, organ transplant rejection and autoimmune diseases.

11. A pharmaceutical composition, characterized in that It comprises a phenyl and biphenyl substituted five-membered heterocyclic compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6, and a pharmaceutically acceptable carrier.

12. The pharmaceutical combination according to claim 11, characterized in that The pharmaceutical preparation form is tablet, capsule, powder, pill, granule, injection, oral solution, syrup, inhalant, ointment, patch or suppository.